


Crohn's Disease Market was valued at USD 11.82 Bn in 2023 and is Projected to reach USD 17.15 Bn By 2031

Crohn's Disease Market to grow from \$11.82B in 2023 To \$17.15B by 2031, at a 4.8% CAGR, driven by rising IBD prevalence and demand for advanced therapies.

AUSTIN, TX, UNITED STATES, May 22, 2025 /EINPresswire.com/ -- Crohn's Disease Market Overview

The Global Industry for [Crohn's Disease Market Size](#) was valued at USD 11.82 billion in 2023 and is anticipated to hit USD 17.15 billion by 2031, expanding at a CAGR of 4.8% between 2024 and 2031.



Crohn's disease, a chronic inflammatory condition of the gastrointestinal tract, continues to affect millions globally. Over the past decade, the market for Crohn's disease treatment has evolved significantly. This shift is largely attributed to the increasing number of diagnosed cases, rising awareness among patients and healthcare providers, and continuous innovation in pharmaceutical therapies. In 2025, the global market for Crohn's disease is estimated to be worth billions, with steady annual growth projected over the next ten years.

“

The U.S. The Crohn's Disease market is witnessing steady growth, driven by rising biologic adoption and early diagnosis valued at over USD 16.14 billion By 2030 with strong future potential.”

DataM Intelligence

This market growth extends across multiple regions and is not confined to just one geographical area. It spans across developed and emerging economies, with North America, Europe, and Asia-Pacific all playing key roles.

Pharmaceutical companies are increasingly investing in

research and development, resulting in the launch of more targeted and effective biologic treatments that offer better outcomes and fewer side effects.

Market Growth and Key Drivers

Several factors are contributing to the growth of the Crohn's disease market. Firstly, the disease is being diagnosed more frequently due to improved awareness and better diagnostic tools. People are more likely now than ever before to seek medical advice for gastrointestinal symptoms, leading to early diagnosis and treatment.

Secondly, the evolution of treatment options has transformed how Crohn's is managed. Traditional anti-inflammatory and immunosuppressant drugs are gradually being supplemented or replaced by biologics—advanced drugs that target specific pathways in the immune system. These therapies not only reduce symptoms but can also delay disease progression.

Patient-centric approaches, personalized medicine, and the use of home-based treatment devices are further enhancing market growth. Many new medications allow patients to self-administer injections at home, which is particularly valuable for people with limited access to regular clinical care.

To Download Sample Report: <https://www.datamintelligence.com/download-sample/crohns-disease-market>

Regional Outlook

North America

North America remains at the forefront of the market, primarily because of its well-developed healthcare system and availability of innovative treatment options. The United States, in particular, is home to many pharmaceutical giants who are actively involved in developing and marketing new treatments for Crohn's disease. Clinical trials, fast-track drug approvals, and insurance coverage also support the market's stability in the region.

Europe

Europe has seen a sharp increase in Crohn's diagnoses over the past few years. Countries like Germany, France, and the United Kingdom are investing more in gastrointestinal health awareness campaigns. Government healthcare systems and partnerships with pharmaceutical firms are helping to make advanced therapies more accessible to European patients.

Asia-Pacific

In the Asia-Pacific region, nations like Japan, China, and South Korea are quickly advancing and narrowing the gap in market development. Rising awareness and improved access to modern treatments are pushing this region forward. Japan, in particular, has become a hub for biosimilar development and commercialization, contributing to affordability and market penetration.

Major Companies in the Market

Several companies are leading the charge in Crohn's disease treatment.

Biogen

Merck & Co

Novartis AG

Janssen Biotech, Inc

Takeda Pharmaceuticals

UCB S.A

AbbVie

Prometheus Laboratories

Market Segmentation By:

By Type Classified into: Ileocolitis, Ileitis, Gastroduodenal Crohn's, Jejunoileitis

By Drug Class Divided into: Anti-inflammatory Drugs, Immunosuppressors, Biologics, Antibiotics, Pain relievers, Others

By Route of Administration: Injectable, Oral

By Distribution Channel Classified into: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

By Region Based on: North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Latest News – USA

The United States has recently seen two major developments in the Crohn's disease space. A breakthrough came with the FDA's approval of a new treatment that offers remission in more than half of patients who previously showed minimal response to standard therapies. This new drug is now being recognized as a game-changer for those with moderate-to-severe Crohn's disease.

Additionally, there has been a push to allow more at-home treatment options. A recently approved injectable medication enables patients to manage their condition without frequent hospital visits. This marks a significant step toward improving quality of life, especially for those in rural or underserved areas. Telehealth programs are also being integrated with treatment plans to ensure that patients receive guidance and follow-ups remotely, further enhancing disease management.

Latest News – Japan

Japan has made impressive strides in the Crohn's disease market. A biosimilar drug designed to replicate the effects of a leading biologic has been approved, making treatment more affordable for a broader range of patients. The availability of this biosimilar has also stirred competition,

encouraging innovation and price reductions in the Japanese pharmaceutical market.

Another important update from Japan involves a comparative study conducted recently. The study highlighted the differences in diagnostic timelines and patient trust levels between Japanese-speaking and English-speaking individuals. Japanese patients were found to be diagnosed quicker and to have higher trust in their healthcare providers. These insights are now being used to refine communication and diagnostic approaches across different regions of the country.

Conclusion

The Crohn's disease market is undergoing a transformative phase. With improved diagnosis, advanced biologic therapies, and better accessibility across various regions, patients today have more options than ever before. Ongoing innovations in treatment and delivery methods are making disease management more efficient and patient-friendly. As regional healthcare systems continue to invest in gastrointestinal health and pharmaceutical companies ramp up R&D, the future of the Crohn's disease market looks optimistic.

From North America's high-tech healthcare systems to Japan's pioneering role in biosimilars, the global landscape is rapidly evolving—bringing hope to millions of individuals managing this chronic illness.

Most Trending Reports By DataM Intelligence:

[Sickle Cell Disease Treatment Market Size, Share 2025](#)

[Alzheimer's Disease Therapeutics Market Size In 2025](#)

Stay informed with the latest industry insights - start your subscription now:

<https://www.datamintelligence.com/reports-subscription>

Sai Kiran

DataM Intelligence 4Market Research

+1 877-441-4866

Sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/815065785>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.